Carl Peterson discusses the potential use of the Galleri test in the insurance industry with Tim Malarkey at the Grail Headquarters.

How the life insurance industry is evolving to help save lives

How the life insurance industry is evolving to help save lives.

Watch Carl Peterson talk about the Galleri test here.

What if someone told you there was a life insurance product that not only insured your life, but could also save it? Would you consider that product over others? Carl Peterson is the chair of the Product Development Group at M Financial Group that dreams up niche and unique offerings to pair with specialized life insurance products tailored for the wealthy and ultra-affluent community that are only available through M Financial firms. One of those ideas came to life when M Financial paired up with GRAIL.

GRAIL has developed the Galleri test, which can identify more than 50 types of cancer with a simple blood draw. The test will tell you if you have cancerous cells in your body, what kind of cancer it is, and predict where it is with 88% accuracy. Other tests are only able to look for specific types of cancer and are often not included in regular screenings. The Galleri test could make testing much more accessible, and lifesaving.

M has partnered with GRAIL, insurance companies, and reinsurance companies to be able to offer the Galleri test as a part of select life insurance products through M’s firms. The test is optional, and if you choose to take it the insurance carrier, its reinsurer, and M will pay for the test. GRAIL will not share the results with your insurance provider, with M, or with Lindberg & Ripple. Regardless of results, taking the test will not affect your policy in any way.

While survival rates vary by cancer type, nearly all types have a substantially higher survival rate if the disease is caught at an early stage. 71% of cancer deaths are caused by cancers without recommended screening. That is why Lindberg & Ripple believes in offering this test, because early detection is a key to survival, and we want to offer that opportunity to our clients. Carl, along with the other Principals of Lindberg & Ripple, were able to take the Grail test for themselves.

“I believe that the future is going to be all about taking the life insurance business from purely being product driven, to being things that surround the product. Things that make the user experience better. How can we be more valuable to our clients outside of just purely a product?” Carl truly cares about his clients, and he cannot think of anything he has done in his business that is as meaningful as being able to offer this test to their clients.
M Financial Group creates these exclusive offerings through their established relationships with carriers. Their commitment to bettering the industry is one of the reasons we are proud to be an M firm. Being a member of M’s board, Carl, Managing Principal of Lindberg & Ripple, was an integral part of bringing this partnership together.


Important safety information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of ​“No Cancer Signal Detected” does not rule out cancer. A test result of ​“Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.